Suzhou, China
AccurEdit Therapeutics, founded in 2021, is pioneering advancements in the field of in vivo gene editing therapies. It focuses on development and commercialization of targeted therapies for severe genetic and acquired diseases. Its flagship products, ART001 (ATTR) and ART002 (PCSK9), are in clinical trials, showcasing potential leadership as Best-in-Class or First-in-Class therapies.
The company boasts a premier technology platform for in vivo gene editing therapies. Notably, AccurEdit is the first Chinese company to progress an LNP-based in vivo gene editing product into human trials and uniquely holds IND clearances both in China and the United States.
While investment specifics are undisclosed, AccurEdit's innovative edge and strategic advancements position it as a promising candidate for investors looking to make impactful investments in the biotechnology sector.
